Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay

Rubin, David T.; Naik, Snehal; Kondragunta, Venkateswarlu; Rao, Tharak; Jain, Anjali

doi:10.1080/03007995.2017.1289908

Cited by 4 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, monitoring SAA levels might be used for detecting anti-drug antibodies even before the loss of response to adalimumab and clinical deterioration. This intriguing finding was recently verified in a large cohort of IBD patients (n=805) receiving adalimumab by Rubin et al (189). SAA concentrations were significantly decreased after introducing adalimumab to therapy.…”

Section: Saa In Ankylosing Spondylitissupporting

confidence: 53%

Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker

2021

View full text Add to dashboard Cite

Serum amyloid A (SAA) is an acute phase protein with a significant importance for patients with inflammatory rheumatic diseases (IRD). The central role of SAA in pathogenesis of IRD has been confirmed by recent discoveries, including its involvement in the activation of the inflammasome cascade and recruitment of interleukin 17 producing T helper cells. Clinical utility of SAA in IRD was originally evaluated nearly half a century ago. From the first findings, it was clear that SAA could be used for evaluating disease severity and monitoring disease activity in patients with rheumatoid arthritis and secondary amyloidosis. However, cost-effective and more easily applicable markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), overwhelmed its use in clinical practice. In the light of emerging evidences, SAA has been discerned as a more sensitive biomarker in a wide spectrum of IRD, especially in case of subclinical inflammation. Furthermore, a growing number of studies are confirming the advantages of SAA over many other biomarkers in predicting and monitoring response to biological immunotherapy in IRD patients. Arising scientific discoveries regarding the role of SAA, as well as delineating SAA and its isoforms as the most sensitive biomarkers in various IRD by recently developing proteomic techniques are encouraging the revival of its clinical use. Finally, the most recent findings have shown that SAA is a biomarker of severe Coronavirus disease 2019 (COVID-19). The aim of this review is to discuss the SAA-involving immune system network with emphasis on mechanisms relevant for IRD, as well as usefulness of SAA as a biomarker in various IRD. Therefore, over a hundred original papers were collected through an extensive PubMed and Scopus databases search. These recently arising insights will hopefully lead to a better management of IRD patients and might even inspire the development of new therapeutic strategies with SAA as a target.

show abstract

Section: Saa In Ankylosing Spondylitissupporting

confidence: 53%

Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker

2021

View full text Add to dashboard Cite

show abstract

“…This current set of methods has made it possible to determine ADA concentrations with higher accuracy and good limits of detection. A number of schemes have further been employed in these methods to allow the analysis of ADAs in the presence of high doses of the corresponding biopharmaceutical or to identify different antibody classes of ADAs [37–39, 41, 71, 78, 84, 88, 91]. However, further work is still needed in this area.…”

Section: Discussionmentioning

confidence: 99%

“…The homogenous mobility shift assay (HMSA) is a method that combines a ligand binding assay with SEC [87][88][89][90][91][92][93]. SEC is a chromatographic technique that can separate target compounds based on their relative sizes and shapes [87,90,92,94].…”

Section: Homogeneous Mobility Shift Assaysmentioning

confidence: 99%

See 1 more Smart Citation

Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review

Suh

Kyei

Hage

2022

J of Separation Science

View full text Add to dashboard Cite

Antibody-based therapeutic agents and other biopharmaceuticals are now used in the treatment of many diseases. However, when these biopharmaceuticals are administrated to patients, an immune reaction may occur that can reduce the drug's efficacy and lead to adverse side-effects. The immunogenicity of biopharmaceuticals can be evaluated by detecting and measuring antibodies that have been produced against these drugs, or antidrug antibodies. Methods for antidrug antibody detection and analysis can be important during the selection of a therapeutic approach based on such drugs and is crucial when developing and testing new biopharmaceuticals. This review examines approaches that have been used for antidrug antibody detection, measurement, and characterization. Many of these approaches are based on immunoassays and antigen binding tests, including homogeneous mobility shift assays. Other techniques that have been used for the analysis of antidrug antibodies are capillary electrophoresis, reporter gene assays, surface plasmon resonance spectroscopy, and liquid chromatographymass spectrometry. The general principles of each approach will be discussed, along with their recent applications with regards to antidrug antibody analysis.

show abstract

Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum

Hock

Smith

McEntyre

et al. 2019

Journal of Immunological Methods

View full text Add to dashboard Cite

Detection of adalimumab and antibodies to adalimumab using a homogeneous mobility shift assay

Cited by 4 publications

References 27 publications

Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker

Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker

Approaches for the detection and analysis of antidrug antibodies to biopharmaceuticals: A review

Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum

Contact Info

Product

Resources

About